Sana Biotechnology(SANA) 最新动态_F10_同花顺金融服务网

最新动态

每股收益： -0.75美元 [[[0,"-0.95"],[1,"-1.16"],[2,"-0.21"],[3,"-0.60"],[4,"-0.75"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u7f8e\u5143"] 每股收益单位：美元查看明细>>	归母净利润： -1.85亿美元同比增长14.86% [[[0,"-2.18"],[1,"-2.67"],[2,"-0.49"],[3,"-1.43"],[4,"-1.85"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u4ebf\u7f8e\u5143"] 净利润单位：亿美元查看明细>>	每股净资产： 0.74美元 [[[0,"1.31"],[1,"1.12"],[2,"0.93"],[3,"0.53"],[4,"0.74"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u7f8e\u5143"] 每股净资产单位：美元查看明细>>	净资产收益率ROE(平均)： -83.15% [[[0,"-21.49"],[1,"-76.76"],[2,"-83.15"]],[[0,"2025\u4e00\u5b63\u62a5"],[1,"2025\u4e2d\u62a5"],[2,"2025\u4e09\u5b63\u62a5"]],""] 总资产报酬率(ROE) 单位：% 查看明细>>
稀释每股收益： -0.75美元 [[[0,"-0.95"],[1,"-1.16"],[2,"-0.21"],[3,"-0.60"],[4,"-0.75"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u7f8e\u5143"] 稀释每股收益单位：美元查看明细>>	营业收入：未披露	每股现金流： -0.42美元 [[[0,"-0.79"],[1,"-1.00"],[2,"-0.22"],[3,"-0.35"],[4,"-0.42"]],[[0,"2024\u4e09\u5b63\u62a5"],[1,"2024\u5e74\u62a5"],[2,"2025\u4e00\u5b63\u62a5"],[3,"2025\u4e2d\u62a5"],[4,"2025\u4e09\u5b63\u62a5"]],"\u7f8e\u5143"] 每股现金流单位：美元查看明细>>	总资产收益率(ROA)： -39.58% [[[0,"-10.44"],[1,"-33.20"],[2,"-39.58"]],[[0,"2025\u4e00\u5b63\u62a5"],[1,"2025\u4e2d\u62a5"],[2,"2025\u4e09\u5b63\u62a5"]],""] 总资产收益率(ROA) 单位：% 查看明细>>

注释：公司货币计价单位为美元

近期重要事件

2025-12-13	详情>> 内部人交易： Wyrick Susan D.共交易2笔
2025-11-06	详情>> 股本变动：变动后总股本26636.61万股
2025-11-06	详情>> 业绩披露： 2025年三季报(累计)每股收益-0.75美元,归母净利润-1.85亿美元,同比去年增长14.86%
2025-10-15	复牌提示： 2025-10-15 10:10:03 停牌，复牌日期 2025-10-15 10:15:03
2025-08-11	详情>> 业绩披露： 2025年中报每股收益-0.6美元,归母净利润-1.43亿美元,同比去年增长9.24%
2025-05-08	详情>> 业绩披露： 2025年一季报每股收益-0.21美元,归母净利润-4938.9万美元,同比去年增长54.05%
2025-04-25	股东大会：将于2025-06-05召开股东大会会议内容 ▼▲ 1.To elect four Class I directors to our Board of Directors (Board), each to serve for a three-year term expiring at the 2028 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The four nominees for election to our Board are Steven D. Harr, M.D., Robert L. Rosiello, Michelle Seitz, CFA, and Patrick Y. Yang, Ph.D.; 2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; 3.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.
2025-03-17	详情>> 业绩披露： 2024年年报每股收益-1.16美元,归母净利润-2.67亿美元,同比去年增长5.82%
2025-03-17	详情>> 业绩披露： 2022年年报每股收益-1.43美元,归母净利润-2.69亿美元,同比去年增长24.29%
2024-11-08	详情>> 业绩披露： 2024年三季报(累计)每股收益-0.95美元,归母净利润-2.18亿美元,同比去年增长-11.56%
2024-08-08	详情>> 业绩披露： 2024年中报每股收益-0.7美元,归母净利润-1.58亿美元,同比去年增长19.56%
2024-08-08	详情>> 业绩披露： 2023年中报每股收益-1.02美元,归母净利润-1.96亿美元,同比去年增长-88.74%
2024-05-08	详情>> 业绩披露： 2024年一季报每股收益-0.49美元,归母净利润-1.07亿美元,同比去年增长-30.87%
2024-04-26	股东大会：将于2024-06-06召开股东大会会议内容 ▼▲ 1.To elect three Class III directors to our Board of Directors (Board), each to serve for a three-year term expiring at the 2027 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The three nominees for election to our Board are Joshua H. Bilenker, M.D., Richard Mulligan, Ph.D., and Mary Agnes (Maggie) Wilderotter. 2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. 3.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.
2024-02-29	详情>> 业绩披露： 2023年年报每股收益-1.46美元,归母净利润-2.83亿美元,同比去年增长-5.11%
2023-11-08	详情>> 业绩披露： 2023年三季报(累计)每股收益-1.01美元,归母净利润-1.95亿美元,同比去年增长-3.23%
2023-04-28	股东大会：将于2023-06-08召开股东大会会议内容 ▼▲ 1.To elect three Class II directors to our Board of Directors (Board), each to serve for a three-year term expiring at the 2026 annual meeting of stockholders or until his or her respective successor is duly elected and qualified. The three nominees for election to our Board are Hans E. Bishop, Robert Nelsen, and Alise S. Reicin, M.D.; 2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023; 3.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.
2022-04-26	股东大会：将于2022-06-06召开股东大会会议内容 ▼▲ 1.To elect four Class I directors to our Board of Directors (our Board), each to serve for a three-year term expiring at the 2025 annual meeting of stockholders. The four nominees for election to our Board are Douglas Cole, M.D., Steven D. Harr, M.D., Michelle Seitz, CFA, and Patrick Y. Yang, Ph.D.; 2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022; 3.To transact any other business properly brought before the Annual Meeting or any adjournment or postponement thereof.
2021-09-06	温馨提示：美股因劳工节，9月6日休市一天

公司新闻

热点新闻更多>>

公司公告更多>>

同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。